Liver cancer
Conditions
Interventions
Liver cancer treatment observation group:None
Sponsors
The First People's Hospital of Foshan
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients eligible for inclusion in this study must meet all of the following criteria: 1.Age >=18 years old and =5cm. 5. Has not received any previous treatment for liver cancer; 6. Those who achieve radical resection (R0) during the operation; 7. Three to seven weeks after surgical resection, independent imaging assessment confirmed no residual lesions; 8. Laboratory tests meet the following conditions, or the following conditions can be achieved after short-term treatment: neutrophil count >=1.5×10^9/L; Hemoglobin >=80g/L; Platelet count >=60×10^9/L; Plasma albumin level >=28g/L; The total plasma bilirubin is lower than three times the upper limit of the normal value. Plasma alanine aminotransferase (ALT) is lower than five times the upper limit of the normal value. The plasma aspartase aminotransferase (AST) is lower than five times the upper limit of the normal value. Plasma creatinine is lower than 1.5 times the upper limit of the normal value. The prothrombin time is normal or exceeds the upper limit of the normal value by no more than 6 seconds. The international normalized ratio (INR) of prothrombin is less than or equal to 2.3; 9. The patient was fully informed of the study and signed the informed consent form.
Exclusion criteria
Exclusion criteria: Patients who meet any of the following criteria are not eligible for this study: Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC 1.HCC recurrence occurred before grouping 2. Have a history of organ transplantation or hepatic encephalopathy 3. Evidence of any residual tumor, recurrence or metastatic disease 4. Patients waiting for liver transplantation 5. Pleural effusion, ascites and pericardial effusion with clinical symptoms requiring drainage 6. Tumor thrombus in the main portal vein (Vp4), or tumor thrombus in the primary branches or above of the inferior vena cava and hepatic vein, or tumor thrombus in the primary branches or above of the bile duct 7. There has been an event of esophageal or gastric variceal bleeding caused by portal hypertension within the past 6 months; Severe (G3) varicose veins were known to have been detected by endoscopic examination within 3 months prior to enrollment. Those with evidence of portal hypertension (including splenomegaly detected by imaging examinations) and assessed by researchers as having a high risk of bleeding 8. Any life-threatening bleeding events that occurred within the past three months, including those requiring blood transfusion treatment, surgery or local treatment, or continuous medication 9. There has been active hemoptysis (at least 2.5ml or 1/2 teaspoon of fresh blood coughed up at one time) within the past 3 months; 10. A history of arterial or venous thromboembolic events within the past 6 months, including myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis or any other serious thromboembolism. Implantable venous port or catheter-derived thrombosis, or superficial venous thrombosis, is excluded in cases where thrombosis stabilizes after conventional anticoagulant therapy. Prophylactic use of small doses of low-molecular-weight heparin (such as enoxaparin 40mg/ day) is permitted. 11. Severe bleeding tendency or coagulation dysfunction, or currently undergoing thrombolytic therapy 12. Patients with acute or chronic active hepatitis B or C infection, with hepatitis B virus (HBV) DNA > 2000IU/ml or 104 copies /ml; Hepatitis C virus (HCV) RNA > 103 copies /ml; Hepatitis B surface antigen (HbsAg) and anti-HCV antibody are both positive.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor-free survival time;Tumor recurrence rate;Recurrence rate of extrahepatic metastasis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Countries
China
Contacts
Public ContactLei Qiucheng
The First People's Hospital of Foshan
Outcome results
None listed